Cabozantinib plus atezolizumab as first-line treatment for advanced kidney cancer

Clinical trial, COSMIC-021, investigated a combination of cabozantinib and atezolizumab in untreated clear-cell renal cell carcinoma (RCC).

There were two groups of patients; one on 60 mg of cabozantinib plus the standard dose of atezolizumab, and the other on 40 mg cabozantinib plus atezolizumab. The results were similar between the two doses and the time taken for the cancer to return (progression-free survival) was 15 months for the 60 mg group and 19 months for the 40 mg group. Response rates were around 55-60%. There was very low progressive disease, which is very important to patients. This treatment failed to work in about one in 20 patients.

Side effects were also very similar between the two treatment groups; however, patient groups were small (around 30 patients).

A new phase 3 study, called CONTACT-03, is now looking at the combination of cabozantinib plus atezolizumab as a second-line treatment.

Watch the video interview on Practice Update here

Share this Post!

Related post